Skip to main content

Advertisement

Table 2 Association between p-Smad2 expression in cancer cells or stromal fibroblasts and clinicopathologic characteristics

From: High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer

   p-Smad2 expression in cancer cells p-Smad2 expression in stromal fibroblasts
Variables Number of patients Low (%) High (%) P Low (%) High (%) P
Gender        
 Male 55 5 (9.1) 50 (90.9) 0.473 32 (58.2) 23 (41.8) 0.346
 Female 23 1 (4.3) 22 (95.7)   16 (69.6) 7 (30.4)  
Age (years)        
 ≤63 41 2 (4.9) 39 (95.1) 0.326 23 (56.1) 18 (43.9) 0.298
 >63 37 4 (10.8) 33 (89.2)   25 (67.6) 12 (32.4)  
Pathologic type        
 Squamous carcinoma 41 2 (4.9) 39 (95.1) 0.560 24 (58.5) 17 (41.5) 0.605
 Adenocarcinoma 29 3 (10.3) 26 (89.7)   20 (69.0) 9 (31.0)  
 Adenosquamous carcinoma 3 0 (0) 3 (100.0)   2 (66.7) 1 (33.3)  
 Large cell carcinoma 5 1 (20.0) 4 (80.0)   2 (40.0) 3 (60.0)  
Pathologic differentiation        
 High 5 0 (0) 5 (100.0) 0.562 4 (80.0) 1 (20.0) 0.679
 Median 50 5 (10.0) 45 (90.0)   30 (60.0) 20 (40.0)  
 Low 23 1 (4.3) 22 (95.7)   14 (60.9) 9 (39.1)  
Clinical Stage*        
 I + II 29 4 (13.8) 25 (86.2) 0.120 20 (69.0) 9 (31.0) 0.300
 IIIA 49 2 (4.1) 47 (95.9)   28 (57.1) 21(42.9)  
  1. *According to Union for International Cancer Control/American Joint Committee on Cancer (6th edition) stage system.